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Exosome therapy for scalp hair growth—A review of the in vivo
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Briana Paiewonsky, BS, Department of Dermatology, University of
Minnesota, Minneapolis, MN and Charles E. Schmidt College of
Medicine at Florida Atlantic University, Boca Raton, FL; Nicole Heinen, BS,
Department of Dermatology, University of Minnesota, Minneapolis, MN;
Gretchen Bellefeuille, BS, Department of Dermatology, University of
Minnesota, Minneapolis, MN; Ora Raymond, BA, Department of Dermatology,
University of Minnesota, Minneapolis, MN; Maria Hordinsky, MD, Department of
Dermatology, University of Minnesota, Minneapolis, MN; Ron Shapiro, MD,
Medical Director of Shapiro Medical Group, Minneapolis, MN and Department of
Dermatology, University of Minnesota, Minneapolis, MN; Ronda Farah, MD,
Department of Dermatology, University of Minnesota, Minneapolis, MN
Background: Exosome therapy is an evolving field that is being investigated for use
in treating hair loss. As no human clinical studies exist, we sought to review the in
vivo and in vitro available preclinical studies.
Methods: A literature search including the terms, ‘‘exosomes and hair,’’ ‘‘exosomes
and alopecia,’’ and ‘‘exosomes and hair loss,’’ was conducted in July 2021 using the
PubMed database. Three reviewers assessed the articles for relevance.
Results: 83 articles resulted. 73 articles were eliminated as they focused on ear rather
than scalp hair, were repeated or reviewed articles, and/or studied extracellular
vesicles instead of exosomes specifically. The remaining 10 articles were reviewed.
All 10 were preclinical studies, and 9 of them suggested positive effects on hair
growth (2 discussed a prolonged anagen phase, 5 discussed increased hair growth, 5
discussed hair related growth factor alterations). Two of the articles discussed in
vivo studies only, 3 of the articles focused on in vitro studies, and 5 included both in
vivo and in vitro studies. All of the in vivo studies were mouse or rat studies, while
the in vitro studies included mouse, goat, or human cells. Only 1 hair loss disease in a
C3H/HeJ mouse model was assessed (alopecia areata), which showed improvement
with exosome use.
Conclusions: The preclinical research including both in vitro and in vivo studies
suggests that exosome therapy could induce hair growth. However, human clinical
studies are needed to verify claims of hair growth prior to exosome therapy initiation
in humans.
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Introduction: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis with an
unknown pathogenesis, being pathergy the main trigger. This disease usually affects
lower extremities and trunk. Head and neck PG is particularly uncommon,
occurring in less than 8% of cases.
Case report: A 51-year-old healthy woman presented with a 2-month history of an
acute, solitary, painful forehead ulcer, that had been previously treated with
systemic antibiotherapy without improvement. The patient reported a traumatism
in that area. No systemic symptoms were present. Physical examination showed an
ulcer of 3 cm in diameter, with vegetative borders and a cribiform wound bed with
pustules. Laboratory tests were normal and bacterial, fungal, and mycobacterial
tissue cultures were negative. Skin biopsy was performed, showing a dense
neutrophilic infiltrate and giant cells. The clinicopathologic diagnosis was facial
PG. The patient underwent systemic therapy with prednisone (0.5 mg/kg/day) with
a dramatic improvement.
Discussion: Facial PG occurs with an abrupt onset in the form of pustules and
papules that rapidly progress into an ulcer. Clinical differential diagnosis includes
mycotic infection, cutaneous tuberculosis, leishmaniasis, malignant tumor, cutaneous lymphoma and factitious dermatitis. Around one third of facial PG cases are
associated with underlying systemic disease. The mainstays of treatment of facial PG
are systemic immunosuppressive agents, being oral corticosteroids or ciclosporin
the treatment of choice. Dapsone, tetraciclines and TNF-a antagonists have also
shown efficacy. Prompt diagnosis of facial PG is essential to initiate treatment and
avoid scars at facial zone, which could have high psychological impact in the patient.
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Vitiligo is a chronic autoimmune disease characterized by the destruction of
melanocytes, resulting in depigmented skin lesions. Epidemiology studies in vitiligo
are often limited to smaller sample sizes and rely on dermatology clinics as the
source population. The population-based Vitiligo and Life Impact Among
International Communities (VALIANT) study sought to understand the natural
history of vitiligo among patients around the world. Here, data from US participants
are presented. Participants were recruited via an online panel. Adults (aged $18
years) who self-reported a vitiligo diagnosis by a health care professional were
eligible to participate. Of 608 US patients, 58% were male; median (range) age at the
time of the survey was 36 (18e83) years. Mean disease duration was 11 years, with a
mean 1.6 years between first noticing lesions and achieving a formal diagnosis. More
than one-third of patients were previously misdiagnosed (37%), with higher rates
among patients with darker skin types (67% for Fitzpatrick types IVeVI). Nearly twothirds (62%) directly sought treatment for vitiligo; vitligo was an incidental finding in
the remaining 38%. Nearly two-thirds (64%) were diagnosed by a dermatologist, or a
nurse practitioner or physician assistant in a dermatology-focused practice. Most
patients (71%) noted a family history of vitiligo (comparable paternal vs maternal).
Median body surface area affected by vitiligo was 4.23%, as measured by the selfassessed Vitiligo Extent Scale. In summary, these findings provide a new perspective
on the diagnosis journey for patients with vitiligo and highlight the need for
accurate, more timely diagnosis.
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There is a paucity of dermatology literature describing motivators and barriers to
patient participation in clinical trials (CTs). This study aimed to identify the degree
of patient awareness and understanding of CTs, and motivators/barrier to CT
participation (CTP) in adults with eczema. The online survey was administered to a
National Eczema Association audience of adults $ 18 years of age with one or more
self-reported forms of eczema. Analysis included univariable and multivariable
logistic regression. Of the 1016 participants (mean age 49.4, SD 18.5), 78.2% were
female (n ¼ 741). The most common race was White (74.4%, n ¼ 694). Those over
65 years old were less likely (aOR:0.5, 95% CI 0.3-0.7) to have considered CTP
compared with those age 18-64 (P \.001). Those with poor/terrible general CT
understanding were less likely (aOR: 0.5, 95% CI 0.3-0.7) to have previous CT
participation versus those with above average understanding. Among participants
with some degree of prior CT exposure (participation, attempt or interest), those
who were Extremely/Very Confident in their ability to find eczema CT information
were more likely (aOR 3.0, 95% CI 1.4-6.8) to have prior CTP compared with those
who were Slightly/Not Very Confident. Race, ethnicity, and rural/urban status were
not associated with CTP. This is the first study in dermatology to identify barriers to
CTP, including age $ 65 years and lack of prior CTP, which may contribute to
decreased CT awareness and understanding. These data may help identify strategies
to improve CTP among a broader demographic and improve trial efficiency, equity,
and generalizability.
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